Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy |
Kwon, Yong-Rim
(Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
Son, Min-Jung (Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) Kim, Hye-Jung (Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) Kim, Yoo-Jin (Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) |
1 | Ohminami H, Yasukawa M, Fujita S: HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95;286-293, 2000. |
2 | Mailänder V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U: Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18;165-166, 2004. DOI ScienceOn |
3 | Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ: Leukemia-associated antigen- specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111;236-242, 2007. |
4 | Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, Goossens H, de Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama H, Berneman ZN: Induction of complete and molecular remissions in acute myeloid leukemia by Wilms tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 107;13824-13829, 2010. DOI ScienceOn |
5 | Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113;6541-6548, 2009. DOI ScienceOn |
6 | Kim YJ, Cho SG, Lee S, Kim MS, Kim EK, Cho BS, Sohn HJ, Choi HB, Eom KS, Min CK, Kim HJ, Kim YG, Kim DW, Lee JW, Min WS, Kim CC, Kim TG: Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML. Bone Marrow Transplant 45;597-599, 2010. DOI ScienceOn |
7 | Van Driessche A, Berneman ZN, Van Tendeloo VF: Active specific immunotherapy targeting the Wilms tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 17;250-259, 2012. DOI ScienceOn |
8 | Roddie C, Peggs KS: Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 11;473-487, 2011. DOI ScienceOn |
9 | Sugiyama H: WT1 (Wilms tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 40;377-387, 2010. DOI ScienceOn |
10 | Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15;5323-5337, 2009. DOI ScienceOn |
11 | Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E: Detection by monoclonal antibodies of the Wilms tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 70;518-523, 1997. DOI ScienceOn |
12 | Baird PN, Simmons PJ: Expression of the Wilms tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25;312-320,1997. |
13 | Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87; 2878-2884, 1996. |
14 | Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100;2132-2137,2002. DOI ScienceOn |
15 | Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, Barrett AJ: T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 11;8799-8807, 2005. DOI ScienceOn |
16 | Houdebine LM: Transgenic animal bioreactors. Transgenic Res 9;305-320, 2000. DOI ScienceOn |
17 | Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE: Isolation, characterization, and expression of the murine Wilms tumor gene (WT1) during kidney development. Mol Cell Biol 11;1707-1712, 1991. DOI |
18 | Fraizer GC, Patmasiriwat P, Zhang X, Saunders GF: Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood 86;4704-4706, 1995. |
19 | Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T, Sugiyama H: Cancer immunotherapy targeting Wilms tumor gene WT1 product. J Immunol 164;1873-1880, 2000. DOI |
20 | Migliaccio AR, Bengra C, Ling J, Pi W, Li C, Zeng S, Keskintepe M, Whitney B, Sanchez M, Migliaccio G, Tuan D: Stable and unstable transgene integration sites in the human genome: extinction of the Green Fluorescent Protein transgene in K562 cells. Gene 256;197-214, 2000. DOI ScienceOn |
21 | Cedar H: DNA methylation and gene activity. Cell 53;3-4,1988. DOI ScienceOn |
22 | Challita PM, Kohn DB: Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A 91;2567-2571, 1994. DOI ScienceOn |
23 | Hoeben RC, Migchielsen AA, van der Jagt RC, van Ormondt H, van der Eb AJ: Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol 65;904-912, 1991. |
24 | Jaenisch R, Schnieke A, Harbers K: Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues. Proc Natl Acad Sci U S A 82;1451-1455, 1985. DOI ScienceOn |
25 | Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG: Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 118;2062-2068, 2011. DOI ScienceOn |
26 | Rosenfeld C, Cheever MA, Gaiger A: WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17;1301-1312, 2003. DOI ScienceOn |
27 | Lake RA, Robinson BW: Immunotherapy and chemotherapy-- a practical partnership. Nat Rev Cancer 5;397-405, 2005. DOI ScienceOn |
28 | Kim HS, Park HM, Park JS, Sohn HJ, Kim SG, Kim HJ, Oh ST, Kim TG: Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine 28;7787-7796, 2010. DOI ScienceOn |
29 | Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS: De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66;1105-1113, 2006. DOI ScienceOn |
30 | Fonsatti E, Nicolay HJ, Sigalotti L, Calabrò L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M: Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 13;3333-3338, 2007. DOI ScienceOn |
31 | Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, Pinto A, Gattei V, Maio M: 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 101;4644-4646,2003. DOI ScienceOn |
32 | Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5;1-10, 2010. |
33 | Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF: In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116;129-139,2010. DOI ScienceOn |
34 | Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C: Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116;1908-1918, 2010. DOI ScienceOn |
35 | Gaiger A, Reese V, Disis ML, Cheever MA: Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96;1480-1489, 2000. |
36 | Grassi G, Maccaroni P, Meyer R, Kaiser H, D'Ambrosio E, Pascale E, Grassi M, Kuhn A, Di Nardo P, Kandolf R, Küpper JH: Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 24;1625-1635, 2003. DOI ScienceOn |
37 | Swindle CS, Klug CA: Mechanisms that regulate silencing of gene expression from retroviral vectors. J Hematother Stem Cell Res 11;449-456, 2002. DOI ScienceOn |